A new survey from Health Union, Migraine In America 2019, finds that people with chronic migraine who currently use a treatment to target calcitonin-gene-related peptides (CGRP) are more likely than those who have never used CGRP therapies to have positive relationships with their healthcare professionals (HCPs) but negative quality of life. The survey illuminates the perspectives and experiences of people impacted by migraine.

Recent Health Union survey data of 2,142 people living with type 2 diabetes showed that 58% of respondents indicated they have experienced burnout related to their condition. Understanding the variety of real-world implications of diabetes burnout can help pharma impact people during critical points of their patient journey--and also reach the people who may be involved in that patient’s care, as well.

Health Union will share research findings based on data and experience from three of the company’s oncology-specific online health communities in presentations at the American Public Health Association (APHA) 2019 Annual Meeting and Expo in Philadelphia.